Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

Investing.com11-22

Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485261367?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 22:21","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485261367","market":"us","top_or_hot":-1,"title":"Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal","media":"Investing.com","content":"<div>\n<p>Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German...</p>\n\n<a href=\"https://finance.yahoo.com/news/halozyme-shares-jump-12-scraps-142144522.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme shares jump 12% as it scraps $2.1 bln Evotec deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/halozyme-shares-jump-12-scraps-142144522.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German...</p>\n\n<a href=\"https://finance.yahoo.com/news/halozyme-shares-jump-12-scraps-142144522.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://finance.yahoo.com/news/halozyme-shares-jump-12-scraps-142144522.html","article_id":"2485261367","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485261367","pubTimestamp":1732285304,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com -Shares of Halozyme Therapeutics  surged 12% at $51.2 before the opening bell on Friday after the company withdrew its 2 billion  proposal to acquire German drug developer Evotec.Earlier this month, Halozyme had offered 11 per share in cash to acquire Evotec, aiming to expand its drug discovery and development portfolio.Halozyme in a statement release on Friday said it was scrapping its plans of acquisition due to its Evotec’s unwillingness to engage in discussions.“We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. However, to date, Evotec has been unwilling to engage with us to explore a potential combination,” said Helen Torley, CEO. Halozyme said it had repeatedly sought to engage with Evotec’s chairwoman to discuss its vision and the benefits of the proposed deal. However, these requests were not accepted.US bars more food, metal imp","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","EVO":"Evotec SE","HALO":"奥洛兹美医疗"},"translate_title":"Halozyme取消21亿美元Evotec交易，股价上涨12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1,"EVO":0.9},"content_text":"Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German drug developer Evotec.\nEarlier this month, Halozyme had offered €11 per share in cash to acquire Evotec, aiming to expand its drug discovery and development portfolio.\nHalozyme in a statement release on Friday said it was scrapping its plans of acquisition due to its Evotec’s unwillingness to engage in discussions.\n“We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. However, to date, Evotec has been unwilling to engage with us to explore a potential combination,” said Helen Torley, CEO\nHalozyme disclosed that it had conducted extensive external due diligence in the months leading up to its proposal. The company also held informal discussions with a member of Evotec's supervisory board, where it expressed interest in a potential business combination.\nHalozyme said it had repeatedly sought to engage with Evotec’s chairwoman to discuss its vision and the benefits of the proposed deal. However, these requests were not accepted.\nRelated Articles\nHalozyme shares jump 12% as it scraps $2.1 bln Evotec deal\nVW labour representatives vote for strikes from early December\nUS bars more food, metal imports over China's alleged forced labor","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485261367"}